

# Neuropathic Pain - Pipeline Review, H1 2018

<https://marketpublishers.com/r/N82E962E766EN.html>

Date: June 2018

Pages: 470

Price: US\$ 2,000.00 (Single User License)

ID: N82E962E766EN

## Abstracts

Neuropathic Pain - Pipeline Review, H1 2018

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H1 2018, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibers could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key

players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 25, 28, 110, 24 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 33 and 2 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Neuropathic Pain - Overview

Neuropathic Pain - Therapeutics Development

Neuropathic Pain - Therapeutics Assessment

Neuropathic Pain - Companies Involved in Therapeutics Development

Neuropathic Pain - Drug Profiles

Neuropathic Pain - Dormant Projects

Neuropathic Pain - Discontinued Products

Neuropathic Pain - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Neuropathic Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd.1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd.2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd.3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd.4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd.5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd.6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd.7), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd.1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd.1), H1 2018

Products under Development by Companies, H1 2018 (Contd.2), H1 2018

Products under Development by Companies, H1 2018 (Contd.3), H1 2018

Products under Development by Companies, H1 2018 (Contd.4), H1 2018

Products under Development by Companies, H1 2018 (Contd.5), H1 2018

Products under Development by Companies, H1 2018 (Contd.6), H1 2018

Products under Development by Companies, H1 2018 (Contd.7), H1 2018

Products under Development by Companies, H1 2018 (Contd.8), H1 2018

Products under Development by Companies, H1 2018 (Contd.9), H1 2018

Products under Development by Companies, H1 2018 (Contd.10), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd.1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd.1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd.2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd.3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd.4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd.1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd.2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd.3), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd.4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd.5), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Neuropathic Pain - Pipeline by AbbVie Inc, H1 2018

Neuropathic Pain - Pipeline by Abide Therapeutics Inc, H1 2018

Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H1 2018

Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H1 2018

Neuropathic Pain - Pipeline by Adynxx Inc, H1 2018

Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H1 2018

Neuropathic Pain - Pipeline by Amneal Pharmaceuticals Inc, H1 2018

Neuropathic Pain - Pipeline by AnaBios Corp, H1 2018

Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H1 2018

Neuropathic Pain - Pipeline by AngioChem Inc, H1 2018

Neuropathic Pain - Pipeline by Aptinyx Inc, H1 2018

Neuropathic Pain - Pipeline by Araim Pharmaceuticals Inc, H1 2018

Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H1 2018

Neuropathic Pain - Pipeline by Artelo Biosciences Inc, H1 2018

Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp, H1 2018

Neuropathic Pain - Pipeline by Astellas Pharma Inc, H1 2018

Neuropathic Pain - Pipeline by AstraZeneca Plc, H1 2018

Neuropathic Pain - Pipeline by Aucta Pharmaceuticals LLC, H1 2018

Neuropathic Pain - Pipeline by BCI Pharma SA, H1 2018

Neuropathic Pain - Pipeline by BCN Peptides SA, H1 2018

Neuropathic Pain - Pipeline by Biogen Inc, H1 2018

Neuropathic Pain - Pipeline by Bionomics Ltd, H1 2018

Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H1 2018

Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H1 2018

Neuropathic Pain - Pipeline by Cavion LLC, H1 2018

Neuropathic Pain - Pipeline by Celgene Corp, H1 2018

Neuropathic Pain - Pipeline by Cellix Bio Pvt Ltd, H1 2018

Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H1 2018

Neuropathic Pain - Pipeline by Cerecor Inc, H1 2018

Neuropathic Pain - Pipeline by CerSci Therapeutics Inc, H1 2018

Neuropathic Pain - Pipeline by Chromocell Corp, H1 2018

Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H1 2018

Neuropathic Pain - Pipeline by Colby Pharmaceutical Co, H1 2018

Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Neuropathic Pain - Pipeline by Daiichi Sankyo Co Ltd, H1 2018



Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H1 2018  
Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H1 2018  
Neuropathic Pain - Pipeline by Eisai Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Eli Lilly and Co, H1 2018  
Neuropathic Pain - Pipeline by Endece LLC, H1 2018  
Neuropathic Pain - Pipeline by Evec Inc, H1 2018  
Neuropathic Pain - Pipeline by Genecode AS, H1 2018  
Neuropathic Pain - Pipeline by GL Pharm Tech Corp, H1 2018  
Neuropathic Pain - Pipeline by Glialogix Inc, H1 2018  
Neuropathic Pain - Pipeline by Grunenthal GmbH, H1 2018  
Neuropathic Pain - Pipeline by GT Biopharma Inc, H1 2018  
Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H1 2018  
Neuropathic Pain - Pipeline by Hydra Biosciences Inc, H1 2018  
Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc, H1 2018  
Neuropathic Pain - Pipeline by India Globalization Capital Inc, H1 2018  
Neuropathic Pain - Pipeline by Intec Pharma Ltd, H1 2018  
Neuropathic Pain - Pipeline by Integral Molecular Inc, H1 2018  
Neuropathic Pain - Pipeline by Intellipharma International Inc, H1 2018  
Neuropathic Pain - Pipeline by Ionis Pharmaceuticals Inc, H1 2018  
Neuropathic Pain - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H1 2018  
Neuropathic Pain - Pipeline by JT Pharmaceuticals Inc, H1 2018  
Neuropathic Pain - Pipeline by Kancera AB, H1 2018  
Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H1 2018  
Neuropathic Pain - Pipeline by Kolon Life Science Inc, H1 2018  
Neuropathic Pain - Pipeline by Komipharm International Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Lexicon Pharmaceuticals Inc, H1 2018  
Neuropathic Pain - Pipeline by Lohocla Research Corp, H1 2018  
Neuropathic Pain - Pipeline by Mapi Pharma Ltd, H1 2018  
Neuropathic Pain - Pipeline by MD Biosciences GmbH, H1 2018  
Neuropathic Pain - Pipeline by Medifron DBT Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by MEDRx Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Merck & Co Inc, H1 2018  
Neuropathic Pain - Pipeline by MindImmune Therapeutics Inc, H1 2018  
Neuropathic Pain - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018  
Neuropathic Pain - Pipeline by Mundipharma International Ltd, H1 2018  
Neuropathic Pain - Pipeline by Nanomerics Ltd, H1 2018  
Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2018



Neuropathic Pain - Pipeline by Neurocentrx Pharma Ltd, H1 2018  
Neuropathic Pain - Pipeline by NeuroCycle Therapeutics GmbH, H1 2018  
Neuropathic Pain - Pipeline by Neurodyn Life Sciences Inc, H1 2018  
Neuropathic Pain - Pipeline by NeuroMax Ltd, H1 2018  
Neuropathic Pain - Pipeline by NeurOp Inc, H1 2018  
Neuropathic Pain - Pipeline by Newron Pharmaceuticals SpA, H1 2018  
Neuropathic Pain - Pipeline by Nippon Chemiphar Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by NoNO Inc, H1 2018  
Neuropathic Pain - Pipeline by Novartis AG, H1 2018  
Neuropathic Pain - Pipeline by Novassay SA, H1 2018  
Neuropathic Pain - Pipeline by OliX Pharmaceuticals Inc, H1 2018  
Neuropathic Pain - Pipeline by Orexigen Therapeutics Inc, H1 2018  
Neuropathic Pain - Pipeline by Patagonia Pharmaceuticals LLC, H1 2018  
Neuropathic Pain - Pipeline by Pfizer Inc, H1 2018  
Neuropathic Pain - Pipeline by Pharmaleads SA, H1 2018  
Neuropathic Pain - Pipeline by Phosphagenics Ltd, H1 2018  
Neuropathic Pain - Pipeline by Quartet Medicine Inc, H1 2018  
Neuropathic Pain - Pipeline by RaQualia Pharma Inc, H1 2018  
Neuropathic Pain - Pipeline by Re-Pharm Ltd, H1 2018  
Neuropathic Pain - Pipeline by Relmada Therapeutics Inc, H1 2018  
Neuropathic Pain - Pipeline by Revance Therapeutics Inc, H1 2018  
Neuropathic Pain - Pipeline by Rottapharm Biotech Srl, H1 2018  
Neuropathic Pain - Pipeline by Saniona AB, H1 2018  
Neuropathic Pain - Pipeline by Shionogi & Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Sollis Therapeutics Inc, H1 2018  
Neuropathic Pain - Pipeline by Sorrento Therapeutics Inc, H1 2018  
Neuropathic Pain - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc, H1 2018  
Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018  
Neuropathic Pain - Pipeline by Theranexus SAS, H1 2018  
Neuropathic Pain - Pipeline by Toray Industries Inc, H1 2018  
Neuropathic Pain - Pipeline by Trevena Inc, H1 2018  
Neuropathic Pain - Pipeline by Vertex Pharmaceuticals Inc, H1 2018  
Neuropathic Pain - Pipeline by Virobay Inc, H1 2018  
Neuropathic Pain - Pipeline by VistaGen Therapeutics Inc, H1 2018  
Neuropathic Pain - Pipeline by Vitality Biopharma Inc, H1 2018  
Neuropathic Pain - Pipeline by Yooyoung Pharm Co Ltd, H1 2018  
Neuropathic Pain - Pipeline by Yuhan Corp, H1 2018

Neuropathic Pain - Dormant Projects, H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.1), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.2), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.3), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.4), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.5), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.6), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.7), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.8), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.9), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.10), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.11), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.12), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.13), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.14), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.15), H1 2018

Neuropathic Pain - Dormant Projects, H1 2018 (Contd.16), H1 2018

Neuropathic Pain - Discontinued Products, H1 2018

Neuropathic Pain - Discontinued Products, H1 2018 (Contd.1), H1 2018

Neuropathic Pain - Discontinued Products, H1 2018 (Contd.2), H1 2018

Neuropathic Pain - Discontinued Products, H1 2018 (Contd.3), H1 2018

Neuropathic Pain - Discontinued Products, H1 2018 (Contd.4), H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Neuropathic Pain, H1 2018  
Number of Products under Development by Companies, H1 2018  
Number of Products under Development by Universities/Institutes, H1 2018  
Number of Products by Top 10 Targets, H1 2018  
Number of Products by Stage and Top 10 Targets, H1 2018  
Number of Products by Top 10 Mechanism of Actions, H1 2018  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018  
Number of Products by Routes of Administration, H1 2018  
Number of Products by Stage and Routes of Administration, H1 2018  
Number of Products by Top 10 Molecule Types, H1 2018  
Number of Products by Stage and Top 10 Molecule Types, H1 2018

### COMPANIES MENTIONED

AbbVie Inc  
Abide Therapeutics Inc  
Acadia Pharmaceuticals Inc  
Achelos Therapeutics Inc  
Adynxx Inc  
Affectis Pharmaceuticals AG  
Amneal Pharmaceuticals Inc  
AnaBios Corp  
Anavex Life Sciences Corp  
AngioChem Inc  
Aptinyx Inc  
Araim Pharmaceuticals Inc  
Arena Pharmaceuticals Inc  
Artelo Biosciences Inc  
Asahi Kasei Pharma Corp  
Astellas Pharma Inc  
AstraZeneca Plc  
Aucta Pharmaceuticals LLC  
BCI Pharma SA  
BCN Peptides SA  
Biogen Inc

Bionomics Ltd  
Can-Fite BioPharma Ltd  
Cara Therapeutics Inc  
Cavion LLC  
Celgene Corp  
Cellix Bio Pvt Ltd  
Centrexion Therapeutics Corp  
Cerecor Inc  
CerSci Therapeutics Inc  
Chromocell Corp  
Circuit Therapeutics Inc  
Colby Pharmaceutical Co  
Crinetics Pharmaceuticals Inc  
Daewoong Pharmaceutical Co Ltd  
Daiichi Sankyo Co Ltd  
Develco Pharma Schweiz AG  
Dompe Farmaceutici SpA  
Eisai Co Ltd  
Eli Lilly and Co  
Endece LLC  
Evec Inc  
Genecode AS  
GL Pharm Tech Corp  
GliaLogix Inc  
Grunenthal GmbH  
GT Biopharma Inc  
GW Pharmaceuticals Plc  
Hydra Biosciences Inc  
Immune Pharmaceuticals Inc  
India Globalization Capital Inc  
Intec Pharma Ltd  
Integral Molecular Inc  
Intellipharma International Inc  
Ionis Pharmaceuticals Inc  
Jeil Pharmaceutical Co Ltd  
Jiangsu Hengrui Medicine Co Ltd  
Jiangsu Nhwa Pharmaceutical Corp Ltd  
JT Pharmaceuticals Inc  
Kancera AB

Knopp Biosciences LLC  
Kolon Life Science Inc  
Komipharm International Co Ltd  
Lexicon Pharmaceuticals Inc  
Lohocla Research Corp  
Mapi Pharma Ltd  
MD Biosciences GmbH  
Medifron DBT Co Ltd  
MEDRx Co Ltd  
Merck & Co Inc  
MindImmune Therapeutics Inc  
Mitsubishi Tanabe Pharma Corp  
Mundipharma International Ltd  
Nanomerics Ltd  
Neurim Pharmaceuticals Ltd  
Neurocentrx Pharma Ltd  
NeuroCycle Therapeutics GmbH  
Neurodyn Life Sciences Inc  
NeuroMax Ltd  
NeurOp Inc  
Newron Pharmaceuticals SpA  
Nippon Chemiphar Co Ltd  
Nippon Zoki Pharmaceutical Co Ltd  
NoNO Inc  
Novartis AG  
Novassay SA  
OliX Pharmaceuticals Inc  
Orexigen Therapeutics Inc  
Patagonia Pharmaceuticals LLC  
Pfizer Inc  
Pharmaleads SA  
Phosphagenics Ltd  
Quartet Medicine Inc  
RaQualia Pharma Inc  
Re-Pharm Ltd  
Relmada Therapeutics Inc  
Revance Therapeutics Inc  
Rottapharm Biotech Srl  
Saniona AB

Shionogi & Co Ltd  
Sollis Therapeutics Inc  
Sorrento Therapeutics Inc  
Sumitomo Dainippon Pharma Co Ltd  
Sunovion Pharmaceuticals Inc  
Teva Pharmaceutical Industries Ltd  
Theranexus SAS  
Toray Industries Inc  
Trevena Inc  
Vertex Pharmaceuticals Inc  
Virobay Inc  
VistaGen Therapeutics Inc  
Vitality Biopharma Inc  
Yooyoung Pharm Co Ltd  
Yuhan Corp

## I would like to order

Product name: Neuropathic Pain - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/N82E962E766EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N82E962E766EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970